Latest News
Connected Thinking
Leading Voices
Latest News
To Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision
PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.
Learn MoreTreating Multiple Myeloma in the Second Line: Which Option Should You Choose?
After first-line multiple myeloma treatment, which strategy is best for second-line therapy?
Learn MoreVenetoclax vs. BTK Inhibitors in CLL Treatment
In 2019, the FDA approved the combination regimen venetoclax (brand name: Venclexta) plus obinutuzumab (brand Name: Gazyva) as a frontline treatment for chronic lymphocytic leukemia (CLL). Though this combination significantly improves progression-free survival compared with obinutuzumab plus the chemotherapy drug chlorambucil, and it’s a time-limited regimen, the multiple infusions and potential side effects warrant careful consideration.
Learn MoreWeighing the Risks of Multiple Myeloma Therapy in the Time of COVID-19
As the COVID-19 pandemic spread across the country, cancer specialists had to weigh the risks of treating multiple myeloma to prevent morbidity and mortality, with the dangers of virus exposure in their patients. SurvivorNet's experts say treatment decisions often hinge on geographic location.
Learn MoreWhat COVID-19 May Have Changed Forever About Multiple Myeloma Care — Telemedicine
COVID made oncologists rethink how to deliver care to their multiple myeloma patients, who are already at higher risk for infection. Providers increasingly shifted to telemedicine, and quickly realized its long-term benefits -- particularly for patients living far from major cancer centers.
Learn MoreWhat Physicians Can Do to Tackle Issues of Race in Cancer Screening and Treatment
Disparities in screenings among those with a family history of cancer are clearly documented in the medical literature. Still, little has changed in our practice to address them.
Learn MoreWhat to Consider Before Prescribing a BTK Inhibitor Such as Calquence for CLL Patients
Bruton kinase (BTK) inhibitors have only emerged in recent years, but already they have become an established therapy for chronic lymphocytic leukemia (CLL) and other hematologic malignancies. Second-generation BTK inhibitors such as acalabrutinib tend to have a better safety profile than the first-generation drugs, but side effects are still a concern.
Learn MoreWhat We’re Learning About Isatuximab and How It’s Being Used to Treat Multiple Myeloma Patients
The recent FDA approval of isatuximab in combination with pomalidomide and dexamethasone has opened up another avenue of treatment for multiple myeloma patients who have already undergone two prior lines of therapy.
Learn More